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sensitive counterparts
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Chronic myeloid leukemia (CML) is a hematological malignancy characterized by high levels of
immature white blood cells. CML is caused by the translocation between chromosomes 9 and 22
(which results in the formation of the Philadelphia chromosome) creating BCR–ABL fusion protein.
Imatinib and nilotinib are chemotherapeutic drugs which specifically bind to the BCR–ABL and
inhibit cancer cells. Nilotinib is more effective in this respect than imatinib. We have shown that
nilotinib induces apoptosis in imatinib-resistant K562 CML cells which have the wild-type BCR–
ABL fusion gene almost to the same extent as it does in the parental sensitive cells by the increase
in caspase-3 enzyme activity and the decrease in mitochondrial membrane potential. This effect
of nilotinib, even in low concentrations, may indicate the efficacy of the usage of nilotinib in
imatinib-resistant CML with less risk of undesired cytotoxic effects in the remaining cells of the
body.
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Introduction
Chronic myeloid leukemia (CML) is a hematological
malignancy in which healthy cells in the bone marrow
are replaced by malignant leukemic cells. The disease
is characterized by elevated numbers of immature
white blood cells. The main cause of CML is a
reciprocal translocation between the long arms of
chromosomes 9 and 22 (creating Philadelphia chro-
mosome, Ph), which results in production of the
BCR–ABL fusion protein.1–3 This fusion protein
shows constitutive tyrosine kinase activity, resulting
in strong oncogenic properties. BCR–ABL protein is
also thought to have significant roles in cell growth,
proliferation, differentiation, migration, adhesion
and prevention of apoptosis.3,4 Thus, targeting this
protein by tyrosine kinase inhibitors is an important
approach for prevention of the leukemogenesis in
CML.5
Imatinib (STI-571, Gleevec) is the first target-
specific drug for the treatment of cancers including
Ph-positive CML and gastrointestinal tumors.6 This
drug specifically binds to the ATP-binding domain of
BCR–ABL fusion protein and prevents its activation
and subsequent phosphorylation of the downstream
proteins.7 Although this drug was a breakthrough for
the treatment of CML, there is increasing number of
cases where patients have developed resistance to the
imatinib treatment. This resistance might be con-
ferred by five known mechanisms.8,9 Most cases of
resistance to imatinib result from mutations in the
drug-binding pocket of the fusion protein.10 Two of
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the mechanisms involve decreased availability of the
drug either by binding to plasma proteins, or by
functioning of the efflux proteins such as P-
glycoprotein on the plasma membrane.11 BCR–
ABL gene amplification is another resistance
mechanism which causes increased levels of fusion
protein reducing the efficacy of the drug in vivo.
Besides the mechanisms stated above, resistance
might be developed independently of BCR–ABL.
Activation of other kinases are implicated in this type
of resistance. We have also shown in our previous
studies for the first time that ceramide metabolizing
genes and their end products are also involved in
imatinib resistance in CML cells. In addition to the
known mechanisms of resistance, clinical cases high-
light that there are still uncharacterized resistance
mechanisms in CML patients.
Nilotinib (AMN107, Tasigna) is a second-
generation tyrosine kinase inhibitor targeting the
BCR–ABL fusion protein. Nilotinib has more favor-
able binding energetics and higher selectivity than the
imatinib.12 Thus, it becomes particularly useful for
the treatment of Ph-positive CML which has devel-
oped resistance to imatinib.13 Usage of increasing
concentrations of chemotherapeutic drugs in the
clinic to treat cancers might possibly cause undesired
cytotoxic effects on the healthy cells. Thus, using the
least drug concentrations possible is the main aim in
the treatment of various cancers. Current study
shows the effects of low concentrations of nilotinib
on both parental sensitive and imatinib-resistant
K562 CML cells which do not have any mutations
in the drug-binding pocket of the BCR–ABL fusion
product.
Methods
Cell lines and growth conditions
Human K562 CML cells were obtained from German
Collection of Microorganisms and Cell Cultures.
K562 cells were maintained in RPMI 1640 growth
medium containing 10% fetal bovine serum and 1%
penicillin–streptomycin at 37uC in 5% CO2. The Ph
z
human K562 cells were exposed to increasing
concentrations of imatinib stepwise for 2 year time
period starting from 50 nM. Subpopulations of cells
those were able to grow in the presence of 3 mM
imatinib, were then selected and referred to as
K562/IMA-3.
Assessment of cellular growth by XTT cell proliferation
assay
The IC50 values of imatinib and nilotinib that inhibit
cell growth by 50% were determined from cell
proliferation plots obtained by XTT cell proliferation
assay (Biological Industries, Israel) as described
previously.1 Briefly, 2 6 104 cells were seeded into
the wells of 96-well plates that contain 200 ml growth
medium in the absence or presence of increasing
concentrations either imatinib or nilotinib, and
incubated at 37uC in 5% CO2 for 72 h. After this,
cell suspensions were treated with 40 ml XTT reagent
for 4 more hours. Then, the absorbances of the
samples under 490 nm wavelength of light were
measured by ELISA reader (Multiskan Spectrum,
Thermo Electron Corporation, Vantaa, Finland). At
the end, IC50 values were calculated from the cell
survival plots.
Measurement of caspase-3 enzyme activity
Caspase-3 enzyme activity was determined using
caspase-3 colorimetric assay (R&D Systems,
Minneapolis, MN, USA). The cells that had been
treated with different concentrations of nilotinib for
72 h were collected by centrifugation at 1000 g for
10 min. Pelleted cells were treated with 100 ml of cold
lysis buffer (61) in order to obtain the cell lysate.
Then, the cell lysates were incubated on ice for
10 min and were centrifuged at 14,000 g for 1 min.
Following the centrifugation, supernatants were
transferred to new microcentrifuge tubes. For mea-
suring caspase-3 enzyme activity, reaction mixture
including 20 ml of assay buffer (65), 25 ml of the
samples, 50 ml of distilled water and 5 ml of caspase-3
colorimetric substrate were applied to the cell
suspensions in 96-well plate and incubated for 2 h
at 37uC in CO2 incubator. Absorbances of the
samples were read under 405 nm wavelength of light
via the ELISA reader (Multiskan Spectrum, Thermo
Electron Corporation).
Detection of the mitochondrial membrane potential
The loss of mitochondrial membrane potential as a
hallmark of apoptosis was detected by JC-1 mito-
chondrial membrane potential (MMP) detection kit
(Cell Technology, Mountain View, CA, USA). First,
the cells treated with different concentrations of
nilotinib were collected by centrifugation at 1000 g
for 10 min. Supernatants were discarded and the
pellets were mixed with 500 ml of JC-1 dye and
incubated at 37uC in 5% CO2 for 15 min. Then the
mixtures were centrifuged at 1000 g for 5 min. Pellets
were resuspended in 2 ml of blank media in order to
remove the excess dye and centrifuged for 5 min at
1000 g. All pellets were resuspended with 500 ml of
blank media and 150 ml from each of them was added
into the black 96-well plate. The aggregate red form
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of the dye which remains within the intact mitochon-
dria has absorption/emission maxima of 585/590 nm
and the monomeric green form of the dye which is
released to the cytoplasm due to the loss of the
integrity of the mitochondrial membrane has absorp-
tion/emission maxima of 510/527 nm. The plate was
read at these wavelengths by fluorescence ELISA
reader (Multiskan Spectrum, Thermo Electron
Corporation).
Sequence analysis of K562/IMA-3 cell line
Total RNA was isolated from three million K562/
IMA-3 cells via NucleoSpin RNA II Kit
(MACHEREY NAGEL GmbH & Co. KG, Du¨ren,
Germany). Then total RNA was converted to cDNA
using M-MuLV Reverse Transcriptase (Fermentas
Life Science, Burlington, Ont., Canada). After that,
polymerase chain reaction (PCR) was performed with
B2B and CA3 primers and PCR product was run in
agarose gel. BCR–ABL band was isolated from gel
by DNA Gel Extraction Kit (Fermentas Life
Science). Afterwards, sequencing PCR was carried
out to the purified product with CA3 primer using
BigDye Terminator V3.1 Cycle Sequencing Kit.
Finally, sequence analysis was carried out (Applied
Biosystems 3130xl).
Results
Cellular growth assessment via XTT cell proliferation assay
IC50 value of imatinib was calculated as 280 nM in
sensitive K562 cells (Fig. 1) and 14,680 nM in
resistant K562/IMA-3 cells (Fig. 2). These results
showed that K562/IMA-3 cells are 52-fold more
resistant as compared to parental sensitive counter-
parts. Proliferation assay in the presence of nilotinib
gave the IC50 values of 42 and 84 nM for sensitive
parental K562 (Fig. 3) and K562/IMA-3 cells
(Fig. 4), respectively.
Measurement of caspase-3 enzyme activity
In order to examine cytotoxic effects of nilotinib on
parental and imatinib-resistant K562 cells, both cells
Figure 1 Effects of imatinib on the growth of K562 cells.
The IC50 concentration of imatinib was calcu-
lated from cell proliferation plots. The XTT
assays were performed using triplicate samples
in at least two independent experiments. The
error bars represent the standard deviations,
and when not seen, they are smaller than the
thickness of the lines on the graphs. Statistical
significance was determined using two-way ana-
lysis of variance, and P,0.05 was considered
significant
Figure 2 Effects of imatinib on the growth of K562/IMA-3
cells. The IC50 concentration of imatinib was
determined by XTT assay for K562/IMA-3 cells
as described. The XTT assays were performed
using triplicate samples in at least two indepen-
dent experiments. The error bars represent the
standard deviations, and when not seen, they
are smaller than the thickness of the lines on
the graphs. Statistical significance was deter-
mined using two-way analysis of variance, and
P,0.05 was considered significant
Figure 3 Effects of nilotinib on the growth of K562 cells.
Cytotoxicity was determined by the XTT cell pro-
liferation test in a 72 h culture. The XTT assays
were performed using triplicate samples in at
least two independent experiments. The error
bars represent the standard deviations, and
when not seen, they are smaller than the thick-
ness of the lines on the graphs. Statistical sig-
nificance was determined using two-way
analysis of variance, and P,0.05 was considered
significant
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were exposed to low concentrations of nilotinib for
72 h and the changes in caspase-3 enzyme activity
were determined. The results revealed that there were
1.29 and 1.25-fold increases in caspase-3 enzyme
activity in 1 nM nilotinib applied K562 and K562/
IMA-3 cells, respectively (Fig. 5). These comparisons
were carried out with the control sample which was
composed of sensitive K562 cells cultured in the
absence of the drug. This result showed the induction
of apoptosis upon drug treatment. The closeness of
those values indicates that apoptosis is induced in
both sensitive and resistant K562 cells at similar
rates. On the other hand, steady state levels of
caspase-3 enzyme activity results showed that there
was 2% decrease in caspase-3 enzyme activity in
K562/IMA-3 cells comparing to K562 cells. When the
K562/IMA-3 cells in the absence and in the presence
of 1 nM nilotinib are compared with each other,
there is 1.27-fold increase in caspase-3 enzyme
activity, indicating that the rate of apoptotic induc-
tion is almost the same with the sensitive cells
(Fig. 5).
Detection of mitochondrial membrane potential
We examined the changes in MMP in response to
nilotinib in K562 and K562/IMA-3 cells exposed to
10 nM nilotinib for 72 h. There were 1.55- and 1.23-
fold increases in cytoplasmic/aggregated JC-1 ratios
in K562 and K562/IMA-3 cells, respectively, as
compared to untreated K562 control (Fig. 6).
Steady state levels of cytoplasmic/aggregated JC-1
were decreased 13% in K562/IMA-3 cells compared
to parental sensitive cells. When we compare changes
in cytoplasmic/aggregated JC-1 in 10 nM nilotinib
applied K562/IMA-3 cells with untreated counter-
parts, there were 1.48-fold increase in cytoplasmic/
aggregated JC-1 ratio (Fig. 6). Again, the close values
indicate the similar amounts of changes in MMP
meaning similar induction of apoptosis. The findings
from MMP detection correspond to the previous
results in which caspase-3 activations were assessed.
Sequence analysis of BCR–ABL gene
Sequence of the BCR–ABL fusion gene was found as
seen in Fig. 7. The sequence was compared with the
known wild-type BCR–ABL and there were not any
mutations in the BCR–ABL of the K562/IMA-3 cells
(Fig. 7)
Figure 4 Effects of nilotinib on the growth of K562/IMA-3
cells. Cytotoxicity was determined by the XTT
cell proliferation test in a 72 h culture. The XTT
assays were performed using triplicate samples
in at least two independent experiments. The
error bars represent the standard deviations,
and when not seen, they are smaller than the
thickness of the lines on the graphs. Statistical
significance was determined using two-way ana-
lysis of variance, and P,0.05 was considered
significant
Figure 5 Percent changes in caspase-3 enzyme activity in
nilotinib exposed K562 and K562/IMA-3 cells.
The results are the means of two independent
experiments. The error bars represent the stan-
dard deviations, and when not seen, they are
smaller than the thickness of the lines on the
graphs. P,0.05 was considered significant
Figure 6 Percentage changes in cytoplasmic/aggregated
JC-1 in nilotinib-treated K562 and K562/IMA-3
cells. The results are the means of two indepen-
dent experiments. The error bars represent the
standard deviations, and when not seen, they
are smaller than the thickness of the lines on
the graphs. P,0.05 was considered significant
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Discussion
This study revealed the cytotoxic and apoptotic
effects of nilotinib on imatinib-resistant CML cells
especially in low concentrations. Results indicate that
the growth of the imatinib-resistant cells is inhibited
and they undergo apoptosis almost as effectively as
the imatinib-sensitive cells.
Imatinib was developed for selective inhibition of
tyrosine kinases expressed in malignant cells.14 Being
selective for cancerous cells, the drug has high success
rates in the treatment of Phz CML.15 With the
increasing number of patients using this drug,
increasing number of cases are being reported in
which imatinib resistance is gained. In such cases, the
dosage of the drug should be increased to have a
therapeutic response against the cancer. Although
imatinib is a target-specific drug, it has dose-
dependent hematological side effects on all hemato-
poietic lineages such as inhibition of platelet derived
growth factor receptor, human stem cell factor
receptor c-kit,16 ABL-related gene17 and ABL tyr-
osine kinases.6,18–20 Non-hematological side effects of
imatinib are not generally important to cause
cessation of the treatment, but the cytotoxic effects
on hematopoietic cells prevent the usage of the drug
in high concentrations to treat resistant cancers.21
Nilotinib was developed after the discovery of
imatinib and it has more effective suppression ability
with the increased specificity to the CML cells.12,22
The mechanism of action is similar to that of
imatinib, but 32 of the known 33 mutations in the
BCR–ABL fusion protein responsible for imatinib
resistance remain ineffective to develop resistance
against nilotinib.23 Enhanced specificity and efficacy
of nilotinib make it possible to obtain similar
amounts of therapeutic effect in lower concentra-
tions, which could only be provided by considerably
high concentrations of imatinib. Imatinib treatment
might not be tolerated well in aged patients, which
brings along the necessity of using a more selective
drug.21,24 Thus, nilotinib became particularly useful
for the treatment of CML, especially in old patients,
and the in the patients with imatinib-resistant
CML.25 Similarly, resistant cells which are unrespon-
sive to imatinib treatment necessitate the usage of a
more powerful drug, which is the nilotinib for these
particular cases.
Although nilotinib is highly specific for malig-
nantly transformed cells, there is still a possibility of
developing adverse effects.23,26 In the clinic, these
adverse effects might limit the dosage of the drug.
Lower drug concentrations are less likely to have
undesired cytotoxicity on the healthy cells. The
results of the present study indicated the efficacy of
little amounts of nilotinib on both imatinib-resistant
and -sensitive cells. Inhibition of cellular growth and
induction of apoptosis by such low concentrations of
nilotinib in CML cells are thus promising for the
treatment with minimum side effects which are
mainly dose-dependent. Obtaining cellular responses,
as in this study, indicates the highly selective
inhibitory effect of nilotinib on CML cells, in spite
of the developed resistance mechanisms against
chemotherapeutic drugs.
The efficacy of nilotinib in the treatment of
imatinib-resistant CML was extensively studied
before.22,27 In those studies, it was shown that
mutations in the ATP binding cassette of BCR–
ABL reduces the binding affinity of imatinib,
while nilotinib binding is not affected by the majority
Figure 7 Sequence of the BCR–ABL fusion gene in K562/IMA-3 cells
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of those mutations. Current study indicates that
nilotinib is not only effective for the treatment of
imatinib-resistant CML with mutations in BCR–
ABL fusion product, but also for the inhibition of
imatinib-resistant CML cells which have the wild-
type BCR–ABL. This effect of nilotinib might
indicate that the other mechanisms of drug resistance
in CML are somehow inadequate for nilotinib. BCR–
ABL activity is known to be important for the
development of CML, but there are also other targets
for inhibition of CML as known.28 In this case
nilotinib might have a role in suppressing alternative
signaling pathways which contribute to the leukemo-
genesis and cancer cell survival in a BCR–ABL
independent manner. Besides those signaling path-
ways, nilotinib might have low efflux rates from the
cell due to its molecular structure and physicochem-
ical properties. Thus, the bioavailability of nilotinib
inside the cytoplasm remains higher, making the drug
possible to exert its function for suppression of the
CML. Future studies could be concentrated on
revealing the possible mechanisms in which nilotinib
overcomes the drug resistance in CML. Taken
together, all these data suggest that nilotinib is
effective for inhibition of Phz CML even in low
concentrations and thus, it may provide a treatment
with the least risk of developing undesired cytotoxic
effects on the remaining cells of the body. The extents
of the changes in both sensitive and resistant cells are
almost the same, indicating that efficacy of the
nilotinib still holds for the CML cases in which
resistance was developed to imatinib.
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